Literature DB >> 11606500

Glutathione S-transferase-pi overexpression is closely associated with K-ras mutation during human colon carcinogenesis.

K Miyanishi1, T Takayama, M Ohi, T Hayashi, A Nobuoka, T Nakajima, R Takimoto, K Kogawa, J Kato, S Sakamaki, Y Niitsu.   

Abstract

BACKGROUND & AIMS: In colorectal adenoma and carcinoma, glutathione S-transferase-pi (GSTP1-1) is highly expressed. K-ras mutation is also known to occur frequently in colorectal adenoma and carcinoma, as well as in the putative precursor of adenoma, aberrant crypt foci (ACF). Further, forced expression of v-H-ras in rat liver epithelial cells has been shown to enhance rat pi-class GST expression. The aim of the present study is, therefore, to investigate the causative relationship between GSTP1-1 overexpression and K-ras mutation in these lesions.
METHODS: Twenty-seven specimens of colorectal carcinoma, 24 of adenoma, and 28 of ACF were examined in this study. The expression of GSTP1-1 or p21(K-ras) was examined by immunohistochemistry. The GSTP1-1 messenger RNA levels were measured by TaqMan reverse-transcription polymerase chain reaction (PCR). K-ras mutation was detected by two-step PCR restriction fragment length polymorphism. v-K-ras transfection to RPMI-4788 colon carcinoma cells was carried out by the lipofection method. Activities of GSTP1-1 promoters containing AP-1 and Sp1 responsive elements in the v-K-ras transfectants were measured by a secreted form of human placental alkaline phosphatase (SEAP) assay. Nuclear protein from these transfectants bound to the GSTP1-1 promoter was analyzed by electrophoretic mobility shift assay (EMSA).
RESULTS: In human colorectal carcinoma, adenoma, and ACF, close association of increased expression of GSTP1-1 with K-ras mutation was observed. v-K-ras transfectants showed significantly higher SEAP activity than that of mock-transfectant activity. EMSA showed specific interaction of AP-1 with promoter of GSTP1-1.
CONCLUSIONS: It is highly plausible that GSTP1-1 overexpression in ACF, colorectal adenoma, and carcinoma is induced by K-ras mutation via AP-1 activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606500     DOI: 10.1053/gast.2001.27982

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.

Authors:  Kewen Hu; Kun Li; Jing Lv; Jie Feng; Jing Chen; Haigang Wu; Feixiong Cheng; Wenhao Jiang; Jieqiong Wang; Haixiang Pei; Paul J Chiao; Zhenyu Cai; Yihua Chen; Mingyao Liu; Xiufeng Pang
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  Proteomic research progress in lymphatic metastases of cancers.

Authors:  Junwei Zong; Chunmei Guo; Shuqing Liu; Ming-Zhong Sun; Jianwu Tang
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

3.  Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue.

Authors:  Zhao-Shan Niu; Mei Wang
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

4.  A distinct metabolic signature of human colorectal cancer with prognostic potential.

Authors:  Yunping Qiu; Guoxiang Cai; Bingsen Zhou; Dan Li; Aihua Zhao; Guoxiang Xie; Houkai Li; Sanjun Cai; Dong Xie; Changzhi Huang; Weiting Ge; Zhanxiang Zhou; Lisa X Xu; Weiping Jia; Shu Zheng; Yun Yen; Wei Jia
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

5.  Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis.

Authors:  Kazunori Otsuka; Rika Satoyoshi; Hiroshi Nanjo; Hideaki Miyazawa; Yuki Abe; Masamitsu Tanaka; Yuzo Yamamoto; Hiroyuki Shibata
Journal:  Oncol Lett       Date:  2011-12-29       Impact factor: 2.967

6.  Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study.

Authors:  Jolantha Beyerle; Andreana N Holowatyj; Mariam Haffa; Eva Frei; Biljana Gigic; Petra Schrotz-King; Juergen Boehm; Nina Habermann; Marie Stiborova; Dominique Scherer; Torsten Kölsch; Stephanie Skender; Nikolaus Becker; Esther Herpel; Martin Schneider; Alexis Ulrich; Peter Schirmacher; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister; Ulrike Haug; Robert W Owen; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

7.  Cdk3-promoted epithelial-mesenchymal transition through activating AP-1 is involved in colorectal cancer metastasis.

Authors:  Jinping Lu; Zhen Lin Zhang; Damao Huang; Na Tang; Yuejin Li; Zhengke Peng; Chengrong Lu; Zigang Dong; Faqing Tang
Journal:  Oncotarget       Date:  2016-02-09

8.  Glutathione S-transferase alpha 4 induction by activator protein 1 in colorectal cancer.

Authors:  Y Yang; M M Huycke; T S Herman; X Wang
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 8.756

9.  Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

Authors:  A Losada; J M López-Oliva; J M Sánchez-Puelles; L F García-Fernández
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

10.  B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P.

Authors:  A Inoue; K Okamoto; Y Fujino; T Nakagawa; N Muguruma; K Sannomiya; Y Mitsui; T Takaoka; S Kitamura; H Miyamoto; T Okahisa; T Fujimori; I Imoto; T Takayama
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.